SK9222000A3 - The use of type i - ifn interferon complex and a subunit of human interferon alpha/beta ifnar receptor for the prolongation of in vivo effect of type i ifn, a molecule comprising such a complex, dna encoding fused protein, host cell and pharmaceutical composition comprising such complex - Google Patents

The use of type i - ifn interferon complex and a subunit of human interferon alpha/beta ifnar receptor for the prolongation of in vivo effect of type i ifn, a molecule comprising such a complex, dna encoding fused protein, host cell and pharmaceutical composition comprising such complex Download PDF

Info

Publication number
SK9222000A3
SK9222000A3 SK922-2000A SK9222000A SK9222000A3 SK 9222000 A3 SK9222000 A3 SK 9222000A3 SK 9222000 A SK9222000 A SK 9222000A SK 9222000 A3 SK9222000 A3 SK 9222000A3
Authority
SK
Slovakia
Prior art keywords
ifn
ifnar
type
complex
sequence
Prior art date
Application number
SK922-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Mark Tepper
Mark Cunningham
David Sherris
Tayar Nabil El
Sean Mckenna
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of SK9222000A3 publication Critical patent/SK9222000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK922-2000A 1997-12-19 1998-12-18 The use of type i - ifn interferon complex and a subunit of human interferon alpha/beta ifnar receptor for the prolongation of in vivo effect of type i ifn, a molecule comprising such a complex, dna encoding fused protein, host cell and pharmaceutical composition comprising such complex SK9222000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (1)

Publication Number Publication Date
SK9222000A3 true SK9222000A3 (en) 2001-01-18

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
SK922-2000A SK9222000A3 (en) 1997-12-19 1998-12-18 The use of type i - ifn interferon complex and a subunit of human interferon alpha/beta ifnar receptor for the prolongation of in vivo effect of type i ifn, a molecule comprising such a complex, dna encoding fused protein, host cell and pharmaceutical composition comprising such complex

Country Status (27)

Country Link
US (1) US6372207B1 (enExample)
EP (1) EP1037658B1 (enExample)
JP (1) JP4601163B2 (enExample)
KR (1) KR100593981B1 (enExample)
CN (1) CN1241638C (enExample)
AR (1) AR020315A1 (enExample)
AT (1) ATE218362T1 (enExample)
AU (1) AU755078B2 (enExample)
BG (1) BG64920B1 (enExample)
BR (1) BR9813753A (enExample)
CA (1) CA2311648C (enExample)
DE (1) DE69805844T2 (enExample)
DK (1) DK1037658T3 (enExample)
EA (1) EA003635B1 (enExample)
EE (1) EE200000355A (enExample)
ES (1) ES2174530T3 (enExample)
HU (1) HUP0100456A3 (enExample)
IL (2) IL136855A0 (enExample)
NO (1) NO20002691L (enExample)
NZ (1) NZ504771A (enExample)
PL (1) PL197568B1 (enExample)
PT (1) PT1037658E (enExample)
SK (1) SK9222000A3 (enExample)
TR (1) TR200001961T2 (enExample)
UA (1) UA74132C2 (enExample)
WO (1) WO1999032141A1 (enExample)
ZA (1) ZA9811634B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
PL1666496T3 (pl) * 2003-08-25 2014-08-29 Toray Industries Kompozyt interferonu beta
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
AU2007351813B2 (en) * 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
WO2010117848A1 (en) 2009-03-31 2010-10-14 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
EP2970461A4 (en) * 2013-03-15 2016-11-23 Janssen Biotech Inc INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
KR20200015742A (ko) * 2017-06-20 2020-02-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 인터페론 전구약물
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
US6372207B1 (en) 2002-04-16
EP1037658B1 (en) 2002-06-05
JP2001526242A (ja) 2001-12-18
AR020315A1 (es) 2002-05-08
EA003635B1 (ru) 2003-08-28
WO1999032141A1 (en) 1999-07-01
BG64920B1 (bg) 2006-09-29
AU755078B2 (en) 2002-12-05
EP1037658A1 (en) 2000-09-27
HUP0100456A3 (en) 2003-09-29
NO20002691L (no) 2000-08-18
BG104539A (en) 2001-04-30
CA2311648A1 (en) 1999-07-01
DK1037658T3 (da) 2002-09-30
HUP0100456A1 (hu) 2001-06-28
CN1241638C (zh) 2006-02-15
DE69805844T2 (de) 2002-10-24
EE200000355A (et) 2001-10-15
ES2174530T3 (es) 2002-11-01
AU1926999A (en) 1999-07-12
KR20010032836A (ko) 2001-04-25
NZ504771A (en) 2002-09-27
ZA9811634B (en) 1999-06-22
PL341423A1 (en) 2001-04-09
CA2311648C (en) 2010-11-16
PT1037658E (pt) 2002-10-31
ATE218362T1 (de) 2002-06-15
DE69805844D1 (de) 2002-07-11
UA74132C2 (uk) 2005-11-15
IL136855A (en) 2007-07-24
HK1032914A1 (en) 2001-08-10
EA200000685A1 (ru) 2000-12-25
PL197568B1 (pl) 2008-04-30
IL136855A0 (en) 2001-06-14
TR200001961T2 (tr) 2000-11-21
KR100593981B1 (ko) 2006-06-30
BR9813753A (pt) 2000-10-10
JP4601163B2 (ja) 2010-12-22
CN1282255A (zh) 2001-01-31
NO20002691D0 (no) 2000-05-25

Similar Documents

Publication Publication Date Title
EP1037658B1 (en) Ifnar/ifn complex
Grace et al. Structural and biologic characterization of pegylated recombinant IFN-α 2b
CN1329082C (zh) 干扰素－β－1a的聚合物缀合物及其使用
US20110189131A1 (en) Active variants of the il-18 binding protein and medical uses thereof
CN101115769A (zh) 干扰素-α多肽和偶联物
US20100239530A1 (en) Ifnar2 mutants, their production and use
Antonelli Biological basis for a proper clinical application of alpha interferons.
US7695710B2 (en) Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
US7662370B2 (en) Low-toxicity, long-circulating human interferon-alpha PEGylated mutants
MXPA00005886A (en) Ifnar2/ifn complex
CZ20002287A3 (cs) Komplex IFNAR2/IFN
AU2002366976B2 (en) IFNAR2 mutants, their production and use

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure